HNRNPA2B1 and Miyoshi myopathy: Also overexpression of HNRNPA2B1 is correlated with poor survival in gastric cancer (GC), multiple myeloma (MM) and ovarian cancer and HNRNPA2B1 acts as an oncogenic role in their progression (Yang et al., 2020; Jiang et al., 2021; Peng et al., 2021).